It’s great to announce the 11th Germany Chapter meeting for 2022 which will be held either
Online on Monday 28 & Tuesday 29 March or as an in-person meeting in Berlin on Tuesday
29 March. Confirmation of the meeting format will be advised in the coming months when
the situation regarding restrictions becomes clearer.
Our convenors have reviewed market trends and feedback from the 2021 Germany meeting
as well as looking at the industry landscape and challenges faced amongst our colleagues.
We would therefore like to receive papers focussing on:
• The unease from clients to be named
The ethics topic is not part of the call for papers – we will shape this session.
• Agility Post Covid
Covid-19 is still very much a part of our lives, we would like to see how
organisations have adapted and pivoted in the covid-19 climate and which of
these trends will remain.
▪ Looking at new tools that emerged due to a change in needs or a
demand for different patient access. How are GPs expected to
change? Will the “old” normal ever be reclaimed?
• Role of the Sales Rep
The role of the pharma Sales Rep over the past 18months has been very fluid
and is only now starting to return to a traditional model. We would like to
explore the differing viewpoints towards the developing Sales Rep role and
how organisation envisage the future of the role. Is it still a crucial part of the
business to consumer relationship or are new methods of communication
making the role less relevant?.
• Behavioural Science
With so much focus on behavioural science, not just in our industry, but in
many areas of society when a change of behaviour is an objective, it’s not
surprising that its principles have been widely adopted. Now is the time to
take stock of what has been achieved, to assess what has been learnt, and
importantly what its future role should be. We are interested in papers that
showcase examples where behavioural principles have been applied and
what value it can bring.
• What role has it played in the creative processes, especially brand
development and communications research?
• What role does it play in encouraging HCPs, patients and other stakeholders
to participate in surveys?
• What is the value of BSci in the selling situation to pharma Company
• How does the power of BSci techniques improve patients drug adherence?
These are only our initial thoughts - we want you to be inspired to develop your own ideas
which reflect the new world of business analysis. We welcome suggestions for other topics –
so don’t feel you have to keep to the list we have included here!
It is great to have variety in our conference in terms of presentation formats and so feel free
to suggest whether your submission would work best as a:
• Presentation • Panel Discussion • TED Talk • Etc
1. SPEAKER INFORMATION
Number of Speakers
EPHMRA accepts 2 speakers per presentation submission.
Panels, debates can of course feature more speakers.
All speakers need to feature on the submission form.
Speaker Registration Fee
• Online event: If the event is held online all speakers are able to attend their speaking
session for free but will need to register and pay to attend the whole event.
• In-person event: Speakers from industry companies are able to have a free
conference registration. For all other speakers, EPHMRA is unable to waive the
conference registration fee or fund any associated travel or personal expenses.
Speakers need to register themselves for the event
At the event (online or in-person) papers will:
• Be presented in German
• Be presented using the EPHMRA conference PPT template, which will be sent
following acceptance onto the programme
• Have a speaking slot of 20-25 minutes + 5 minutes for Q&A
You will receive more details in the Speaker Guidelines which we will email to those who are
successful as securing a speaking slot.
2. TIPS FOR A SUCCESSFUL SUBMISSION
A successful paper is:
• Is thought provoking, innovative, forward looking or controversial in nature
• Offers solutions and recommendations based on the problem addressed
• Demonstrates how a specific process, technique or approach can impact on the
• Is appropriate to an international audience
It is assumed that all presenters have ensured that permission has been obtained from
clients or other third parties to present the information (this includes, music, drawings,
visuals etc.) contained in the paper and/or the final presentation. The presenters will
indemnify EPHMRA and will ensure that EPHMRA is not held liable for any claims from
clients or other third parties incurred by the author’s failure to obtain permission to use
information. The authors should also be sure there is no infringement upon the copyright,
right of use or any other right of intellectual property under any circumstances.
PLEASE ENSURE: You give a clear and detailed picture of the intended full paper to enable
judgement of the quality of the final presentation output. Outline the main argument to be
put forward, describe the case study and/ or data which will be used to support the
argument, present the major findings or conclusions and list any published papers which will
be referred to.
State clearly the key take away messages from your paper – what will the audience be able
to do differently when back in the office.
Submit your speaking ideas online by 20 October 2021.
A receipt should be received by email within 2 working days - if not then please contact
EPHMRA to check if the document has been received - this is very important as each year at
least one submission is not received by EPHMRA.
If you are submitting supporting files, then please ensure that you indicate on your
submission (and in your email) what you are proposing to send, so that we can be sure to tie
up your submission.
3. WHAT HAPPENS AFTER YOU SUBMIT?
The submissions are all formatted and then evaluated by the meeting convenors and in
November we will contact you about the Convenors decision.
The outcomes can be:
1. Acceptance onto the programme without revisions
2. Acceptance onto the programme with revisions
3. Your submission is not able to be accepted onto the programme, with some
guidance on why this decision was reached.
In the meantime, please do contact us with any queries [email protected]